The Combination of Sirolimus and Cyclosporine Does Not Delay Initial Renal Graft Function Recovery

Figures & data

Table 1 Clinical features of donors and renal transplant recipients divided according to the immunosuppressive regimen adopted

	SRL group (N = 21)	Control (N = 40)	p value
Age (y)	39 ± 11	37 ± 9	0.492
Gender (M/F)	10/11	24/26	0.355
Diabetes	2	1	0.228
Hypertension	5	10	0.918
Dialysis duration (days)	375 ± 250	387 ± 183	0.832
Pre-transplant data
Hemoglobin (g/dL)	11.3 ± 1.6	10.6 ± 1.9	0.210
Albumin (g/dL)	3.9 ± 0.2	3.8 ± 0.6	0.405
Calcium (mg/dL)	10.1 ± 0.8	10.2 ± 0.9	0.594
Creatinine (mg/dL)	10.8 ± 3.1	10.4 ± 3.5	0.655
BUN (mg/dL)	63 ± 23	62 ± 27	0.844
Kt/V	1.71	1.63	0.842
Donor age (y)	28 ± 12	36 ± 14	0.038^*
HLA mismatch	2.14 ± 1.4	2.20 ± 1.2	0.866
Delayed graft function (%)	6 (28)	10 (25)	0.763
Acute rejection (%)	5 (23)	8 (20)	0.730
Post-transplant two year GFR (mL/min)	53.1 ± 19.1	51.6 ± 24.8	0.812
Post-transplant dialysis duration (days)	3.7 ± 6.5	3.3 ± 6.3	0.843
Two-year graft failure (%)	1 (4)	2 (5)	0.967
Two-year mortality (%)	0 (0)	1 (2.5)	0.465

p values are based on chi-square test for categorical variables, analysis of variance for continuous variables.

*p < 0.05

Figure 1. Kidney graft function in the two groups of patients examined at one, two, three, and four weeks after transplantation.

Figure 2. Kidney graft function in the two groups of patients examined at 6, 12, 18, and 24 months after transplantation.